Testosterone therapy for women lacks FDA approval, leaving menopause patients facing insurance denials and imprecise dosing. U.S. regulators met this week to evaluate safer access.
Testosterone therapy for women lacks FDA approval, leaving menopause patients facing insurance denials and imprecise dosing. U.S. regulators met this week to evaluate safer access.
